Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT03982121
Other study ID # 2017-005020-14
Secondary ID 2017/2630
Status Withdrawn
Phase Phase 1
First received
Last updated
Start date June 4, 2019
Est. completion date February 12, 2020

Study information

Verified date February 2020
Source Gustave Roussy, Cancer Campus, Grand Paris
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To determine the maximum tolerated dose (MTD), the recommended phase 2 dose (RP2D) and the toxicity profile (NCI CTCAE v5.0 and immune related adverse events) of i.t. administration of anti-CTLA4 antibody (ipilimumab) and TLR4 agonist (synthetic glucopyranosyl lipid A formulated in a stable emulsion [GLA-SE]) in colorectal LM (CRLM) in combination with intravenous (i.v.) administration of anti-PD-1 antibody (nivolumab) and chemotherapy (FOLFOX regimen).


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date February 12, 2020
Est. primary completion date February 12, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Histologically confirmed colorectal adenocarcinoma.

2. At least one CRLM

- measurable according to RECIST 1.1,

- at least >2 cm in maximal diameter,

- visible on non-contrast enhanced computerized tomography (CT) scan or ultrasonography,

- amenable to biopsy,

- and amenable to percutaneous i.t. injection.

3. At least one other metastasis (controlateral CRLM or a distant visceral or lymph node metastasis)

- measurable according to RECIST 1.1,

- and amenable to biopsy.

4. Tumor lesions located in previously irradiated areas are considered measurable if disease progression has been demonstrated in such lesions.

5. Tumor liver involvement <50% on baseline CT scan.

6. Previous failure of active drug classes in mCRC (fluoropyrimidines, oxaliplatin, irinotecan, EGFR inhibitors [if wild-type RAS mCRC] and antiangiogenics).

7. Representative tumor specimens at the initial diagnosis of CRC (paraffin blocks (preferred) or at least 10 unstained slides), with the corresponding pathology report, if available.

8. Age >/=18 years.

9. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1

10. Expected life expectancy >3 months (no rapidly progressive disease).

11. Adequate organ functions:

- Hemoglobin =9 g/dL or =5.6 mmol/L (blood cell transfusions are allowed), absolute neutrophil count (ANC) =1.5 x 109/L, platelets =100 x 109/L

- Serum creatinine =1.5 X upper limit of normal (ULN) or creatinine clearance (measured, or calculated per institutional standard) =50 mL/min for subject with creatinine levels >1.5 x institutional ULN (glomerular filtration rate can also be used in place of creatinine or creatinine clearance)

- Serum total bilirubin =1.5 ULN or direct (unconjugated) bilirubin =ULN for subjects with total bilirubin levels >1.5 ULN

- AST (SGOT) and ALT (SGPT) =5 ULN

- Albumin >33 g/L

- International normalized ratio (INR) or prothrombin time (PT) =1.5 ULN unless subject is receiving anticoagulant therapy as long as PT or activated partial thromboplastin time (aPTT) is within therapeutic range of intended use of anticoagulants

12. Female subjects of childbearing potential should have a negative urine or serum pregnancy test within 24 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.

13. Female subjects of childbearing potential should be willing to use two validated methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 7 months after the last dose of study medication (Reference Section 5.9.2). Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year.

14. Sexually active male subjects unless surgically sterile, must agree to use condoms as an effective barrier method of contraception or abstain from heterosexual activity for the course of the study through 7 months after the last dose of study medication. It is recommended that their sexual partners use an effective contraceptive during the same period.

15. Signed informed consent.

16. Affiliation to or beneficiary of a social security system.

Exclusion Criteria:

1. Allergy or contraindication to oxaliplatin (including peripheral neuropathy [= grade 2]), fluorouracil (including known dihydropyrimidine dehydrogenase (DPD) deficiency) or leucovorin or to any other study drug.

2. Prior history of intolerance to full-dose FOLFOX regimen.

3. History of anterior organ transplantation, including allograft stem cell transplantation

4. History of interstitial lung disease

5. Patients eligible for curative-intent local therapies (e.g., surgery or thermablation).

6. Contraindication to percutaneous injection/biopsy (e.g., coagulation disorder, anticoagulant or antiaggregant therapy). Patients treated with low molecular weight heparin (LMWH) are eligible if they can interrupt their treatment for biopsies and i.t. injections.

7. Concomitant administration of any other anticancer therapy during the trial treatment period.

8. Prior chemotherapy, targeted therapy or radiation therapy within 2 weeks prior to study Day 1 or adverse events due to a previously administered agent that have not recovered (i.e., = Grade 1) at baseline.

9. Immunodeficiency or systemic steroid therapy equivalent to prednisolone >10mg/day or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.

10. Other malignancy within 2 years prior to enrollment with the exception of curatively treated basal-cell carcinoma of the skin, squamous-cell carcinoma of the skin, and/or curatively resected in situ cervical and/or in situ breast cancers.

11. Symptomatic active central nervous system metastases and/or carcinomatous meningitis.

12. Active automimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents. Subjects with vitiligo or asymptomatic asthma/atopy under topical/aerosol therapies would be an exception to this rule. Subjects who require intermittent use of bronchodilators or local steroid injections would not be excluded from the study. Subjects with stable hypothyroidism on hormone replacement or Sjogren's syndrome will not be excluded from the study. Patients with controlled type 1diabetes mellitus on a stable insulin regimen may be eligible for this study.

13. Active infection requiring systemic therapy.

14. Pregnancy or breastfeeding, or inadequate contraceptive method, or expectation to conceive children within the projected duration of the trial, starting with the pre-screening or screening visit through 7 months after the last dose of trial treatment.

15. Prior immunotherapy, including anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibodies (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways).

16. Clinically significant liver disease (i.e., with clinical, biological or morphological signs or symptoms of liver dysfunction, such as jaundice, hepatic encephalopathy, non-malignant ascites, radiological/endoscopic evidence of portal hypertension, biological evidence of liver insufficiency, etc.), including active viral, alcoholic, or other hepatitis, cirrhosis, severe oxaliplatin-induced sinusoidal obstruction syndrome (SOS) and inherited liver disease.

17. Known active Hepatitis B virus infection (e.g., HBsAg reactive) or Hepatitis C virus infection (e.g., HCV RNA [qualitative] is detected) and positive Hepatitis test results.

18. Known history of Human Immunodeficiency Virus (HIV) (HIV 1 and 2 antibodies) and positive HIV test results.

19. Administration of a live vaccine within 30 days prior to the first dose of trial treatment.

20. Any physical, psychological or social condition/reason that would preclude adequate follow-up or hamper patient's safety according to the investigator's opinion.

21. Patient under guardianship or deprived of his liberty by a judicial or administrative decision or incapable of giving its consent

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
FOLFOX regimen
Oxaliplatin 85 mg/m² Leucovorin (LV) levogyre form (LLV) 200 mg/m² or dextro-levogyre (DL-LV) racemic mixture 400 mg/m²) Fluorouracil 2400 mg/m²
Nivolumab
Nivolumab 240 mg
Ipilimumab
Ipilimumab 5 or 10 or 25 mg
GLA-SE
GLA-SE 1 or 2 or 5 or 10 or 20 µg

Locations

Country Name City State
France Gustave Roussy Villejuif Val De Marne

Sponsors (1)

Lead Sponsor Collaborator
Gustave Roussy, Cancer Campus, Grand Paris

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum tolerated dose (MTD) MTD will be determined based on the DLT definitions and identified as the maximum dose level at which less than 33% of DLT are observed in the evaluable patients. For all the cohorts, the DLT period to determine the MTD will be 28 days
Primary Recommanded phase 2 dose (RP2D) RP2D will be determined based on the MTD identified, on analysis of DLT defining events RP2D will be assessed on 8 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT03941080 - Gut Microbiome Dynamics in Metastasized or Irresectable Colorectal Cancer
Completed NCT03213314 - HepaT1ca: Quantifying Liver Health in Surgical Candidates for Liver Malignancies N/A
Completed NCT03647839 - Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal Cancer Phase 2
Recruiting NCT05057052 - Cryoablation Combined With Sintilimab Plus Regorafenib In Previously Treated Colorectal Cancer Liver Metastasis Phase 2
Terminated NCT02316496 - Rechallenge of Cetuximab Combined With Irinotecan as Third-line Chemotherapy in Patients With Metastatic Colorectal Cancer - Phase II Study Phase 2
Completed NCT03251612 - Predictive Value of Drug Sensitivity Testing Tumorspheres From Patients With Metastatic Colorectal Cancer Phase 2
Completed NCT02380443 - AlloStim® Immunotherapy Dosing Alone or in Combination With Cryoablation in Metastatic Colorectal Cancer Phase 2
Recruiting NCT02149784 - Effectiveness Study of Resection of Primary Tumor in Stage IV Colorectal Cancer Patients Phase 3
Recruiting NCT01959061 - Efficacy and Safety of Raltitrexed-based Transarterial Chemoembolisation(TACE)for Colorectal Cancer Liver Metastases Phase 4
Terminated NCT01668680 - Maintenance Metronomic Chemotherapy for Metastatic Colorectal Carcinoma Phase 2
Recruiting NCT05068531 - Early Detection of Treatment Failure in Metastatic Colorectal Cancer Patients
Not yet recruiting NCT04525807 - Precision Medicine for Colorectal Cancer Liver Metastasis Guided by Multi-omics Data Under the Umbrella Theory
Completed NCT04482608 - The mCRC Patients With pMMR/MSS or dMMR/MSI-H Status Received Palliative Chemotherapy Efficacy and Survival
Recruiting NCT03193710 - The Effects of General Anesthetics on Lymphocytes in Patients Undergoing Colorectal Cancer Resection and Mechanism Involved N/A
Recruiting NCT04854213 - PRELUDE-1 (Prospective Evaluation of Radiotherapy-induced Biologic Effects in Colorectal Cancer Oligometastatic Patients With LUng-limited Disease: Evolution of Cancer Genetics and Regulatory Immune Cells) N/A
Suspended NCT04108481 - Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer Phase 1/Phase 2
Completed NCT03142516 - FOLFIRI + Panitumumab First-line Treatment in Elderly Patients With Unresectable Metastatic Colorectal Cancer, RAS/BRAF Wild-type and Good Performance Status Phase 2
Completed NCT03144804 - A Phase 2 Study of Lamivudine in Patients With p53 Mutant Metastatic Colorectal Cancer Phase 2
Active, not recruiting NCT01910610 - Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer Phase 3
Recruiting NCT05759728 - A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer Phase 1/Phase 2